Apolipoprotein D is associated with long-term outcome in patients with schizophrenia

Thomas Folkmann Hansen, R P Hemmingsen, A G Wang, L Olsen, S Timm, Karen Søeby, K D Jakobsen, M Fenger, J Parnas, H B Rasmussen, Thomas Mears Werge

18 Citations (Scopus)


Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.
Original languageEnglish
JournalPharmacogenomics Journal
Issue number2
Pages (from-to)120-5
Number of pages6
Publication statusPublished - 2006


  • Adult
  • Antipsychotic Agents
  • Apolipoproteins
  • Apolipoproteins D
  • Case-Control Studies
  • DNA
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Polymorphism, Single Nucleotide
  • Risk Factors
  • Schizophrenia
  • Time Factors
  • Treatment Outcome


Dive into the research topics of 'Apolipoprotein D is associated with long-term outcome in patients with schizophrenia'. Together they form a unique fingerprint.

Cite this